Organization
Novartis AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Novartis AG
... ACS does not endorse any service or product. About Novartis Social Business Novartis Social Business is part of Novartis, one of the world's largest healthcare ...
... case any one particular sector gives up the ghost." Regeneron CEO on Novartis competition Recent competition from Novartis AG hasn't phased Dr. Leonard Schleifer, the ...
... pharmaceutical companies such as Amgen, Bristol-Myers Squibb, Johnson & Johnson, Pfizer Inc, Novartis AG, Eli Lilly, Merck and Co, Takeda Pharmaceutical, Wyeth, Sanofi, AbbVie Inc. ...
... IP protection: Asset portfolio review: Promacta® sales have continued to accelerate under Novartis, trending to a record $850 million in 2017. Consensus sell-side estimates project ...
... Novartis in August published findings from the phase 3 Cantos trial of Ilaris ...
... Basel- Novartis today announced positive topline results from the global MONALEESA-7 trial, the second ...
... and in the advanced first-line and second-line setting Basel, November 14, 2017- Novartis will present data across its breast cancer portfolio and pipeline in a ...
... is under review by the FDA Holzkirchen, November 14, 2017- Sandoz, a Novartis division and the global leader in biosimilars, today announces data from four ...
... release with multimedia content can be accessed here: Basel, November 13, 2017- Novartis today announced results from a new analysis of the Phase III CANTOS ...
... Novartis has penned a new deal with Homology Medicines as it looks to ...
... for treatment of patients with inflammatory CV risk London, November 13, 2017- Novartis has had a strong year in innovation with several key approvals and ...
... release with multimedia content can be accessed here: Basel, November 10, 2017- Novartis, a global leader in ophthalmology, announced further positive results from two Phase ...
... been clarified and addressed, the drugmaker added. Hikma’s lengthy delay could make Novartis’ Sandoz a come-from-behind winner in the race to bring a cheap copy ...
... Princeton - Sandoz, a Novartis division and the global leader in biosimilars, today announces results from the ...
... million IPO in 2016, while CoStim and Adheron were snapped up by Novartis and Roche, respectively, over the two preceding years. Roche paid $105 million ...
... industry, the latest being the Head of the Ophthalmology Franchise Europe at Novartis AG. She obtained a master degree in business engineering at the University ...
... will be presented at San Antonio Breast Cancer Symposium (SABCS) in December; Novartis plans to initiate discussions with regulatory authorities Basel, November 8, 2017- Novartis ...
... early-stage life science companies and venture firms—from ex-Biogen chief George Scangos, former Novartis leader David Epstein, former Allergan oncology VP Stephen Eck, Clovis Andrew cofounder ...
... Opinion Leader Marketed Therapies Rituxan/MabThera (rituximab; Roche) Gazyva/Gazyvaro (obinutuzumab; Roche) Arzerra (ofatumumab; Novartis) Imbruvica (ibrutinib; Janssen Biotech/AbbVie) Zydelig (idelalisib; Gilead) Venclexta/Venclyxto (venetoclax; AbbVie/Roche) Truxima* (CT-P10; ...
... approved CAR-T therapy * Building on the US r/r B-cell ALL experience, Novartis is working closely with EMA and European treatment centers to make CTL019 ...
... release with multimedia content can be accessed here: Basel, November 6, 2017- Novartis announced today new long-term Cosentyx(R) (secukinumab) data for patients with ankylosing spondylitis ...
... drugs market. For instance, the patent for Gilenya, a blockbuster drug by Novartis, will expire in 2019. This drug led to USD 3.1 billion in ...
... in the first place? That’s the marquee goal that drug making giants Novartis and Amgen are striving for in a project with the Banner Alzheimer's ...
... GlaxoSmithKline plc, Horizon Discovery Group PLC, Merck & Co, New England Biolabs., Novartis AG, Novo Nordisk A/S, Pfizer Inc and Profacgen. Components Covered: o Rest ...
... with one new case diagnosed every three seconds[1],[2] Basel, November 2, 2017- Novartis, Amgen and the Banner Alzheimer's Institute (BAI) today announced an expanded collaboration ...
... Novartis AG is considering a sale of its dermatology generics drugs business and ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤